Close

Acadia Pharma (ACAD) Tops Q1 EPS by 11c

May 5, 2021 4:35 PM EDT

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.42), $0.11 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $106.6 million versus the consensus estimate of $111.63 million.

Reiterating FY21 net sales guidance of $510 to $550 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings